ADC BioMedical Corp. Developing a New Cannabis Formulation – LPC

ADC Biomedical Corp. will sell CanaQuest's Mentabionl.

When ADC BioMedical Corp. received its Health Canada medical sales licence on August 23, 2019, it was a good day for its parent company too. CanaQuest Medical Corp., formally Algae Dynamics Corp., develops “unique health products and nutraceuticals” from hemp, cannabis, and algae oils.

CanaQuest President Paul Ramsay that the sales licence will allow the company to bring their new formulation to market. “As a licence holder under the (Cannabis Act), our company can now target the introduction of… Mentabinol.”

Mentabinol will be CanaQuest’s first proprietary cannabis THC and botanical formulation sold through ADC BioMedical Corp. Its “novel” formulation provides “a better alternative for recreational and medicinal consumers”, the company said in a press release. (Please see link to full press release below.)

“Given the increasing use of medical marijuana for the treatment of a wide variety of ailments, there is an urgent need for safer THC formulation that lacks the neurocognitive and neuropsychiatric side-effects associated with (cannabis) usage,” Ramsay said. ADC BioMedical Corp. will be able to provide that alternative.

The Science Behind Mentabinol – LPC

It’s no secret that cannabis contains THC, the psychoactive compound that gives users the “high”. However, for medicinal use, this can be a problem, Ramsay said. This formulation reduces those effects, the company said.

“THC is associated with a wide range of deleterious neuropsychiatric side-effects in both adolescent and adult users of cannabis.” Those effects can worsen over time. Recreational users can choose not to use cannabis, but for medical patients, the choice may not be that easy.

“Chronic or acute THC exposure has been shown to increase anxiety, increase depressive symptoms, increase vulnerability to schizophrenia-related symptoms.” These can “produce profound cognitive side effects such as deficits in cognitive filtering and memory impairments.”

ADC BioMedical Corp. does not say exactly how it works. It mentions Dr. Steve Laviolette developed it through a partnership with scientists at Western University in London, Ont.

The company filed an international patent for Mentabinol on September 17, 2019. The new formulation will be available December 17, 2019, according to ADC BioMedical Corp.’s press release.

This editorial content from the LPC News Team is meant to provide analysis, insight, and perspective on current news articles. To read the source article this commentary is based upon, please click on the link below.

Leave a Reply